ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells

Breast Cancer Research and Treatment

Volumn 132, Issue 1, 2012, Pages 109-119

  Aird, Katherine M ^a,c   Allensworth, Jennifer L ^a   Batinic Haberle, Ines ^a   Lyerly, H Kim ^a,b   Dewhirst, Mark W ^a,b   Devi, Gayathri R ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Antioxidants; Caspases; IBC; Lapatinib; Reactive oxygen species; Redox modulators; SOD; SUM149; SUM190; Superoxide; Therapeutic resistance; XIAP

Indexed keywords

2 METHOXYESTRADIOL; ADENYLATE KINASE; COPPER ZINC SUPEROXIDE DISMUTASE; DIETHYLDITHIOCARBAMIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLUTATHIONE; GW 583340; HYDROETHIDINE; HYDROGEN PEROXIDE; LAPATINIB; MANGANESE SUPEROXIDE DISMUTASE; PARAQUAT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFLAMMATORY BREAST CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEOSOME; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIOXIDANTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXIDATIVE STRESS; QUINAZOLINES; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SULFONES; SUPEROXIDE DISMUTASE;

EID: 84857910161     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1568-1     Document Type: Article

References (49)

1. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9-23 (Pubitemid 44308938)
2. Woodward WA, Cristofanilli M (2009) Inflammatory breast cancer. Semin Radiat Oncol 19:256-265
3. Van den Eynden GG, Van der Auwera I, Van Laere S, Colpaert CG, van Dam P, Merajver S, Kleer CG, Harris AL, Van Marck EA, Dirix LY et al (2004) Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 85:13-22 (Pubitemid 38437979)
4. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-6263
5. Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q et al (2006) Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 66:1640-1647 (Pubitemid 43259948)
6. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ et al (2008) Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68:7905-7914
7. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, John-Williams LS, Koch KM, Serabjit-Singh CJ (2008) The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methylsulfonyl)ethyl] amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 36:695-701 (Pubitemid 351468376)
8. Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS (2007) Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA 104:10607-10612 (Pubitemid 47185712)
9. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML et al (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066-1072
10. Chen FL, Xia W, Spector NL (2008) Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 14:6730-6734
11. Aird KM, Ghanayem RB, Peplinski S, Lyerly HK, Devi GR (2010) X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol Cancer Ther 9:1432-1442
12. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J et al (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103:7795-7800
13. Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB et al (2008) Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol Pharmacol 74:807-822
14. Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, Moseley MA 3rd, Thompson JW, Chen FL, Koch KM et al (2010) Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol Cancer Ther 9:292-299
15. Hardie DG (2004) The AMP-activated protein kinase pathway - new players upstream and downstream. J Cell Sci 117:5479-5487
16. Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL, Bacus SS (2008) Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 7:1769-1775 (Pubitemid 351988742)
17. Holcik M, Lefebvre C, Yeh C, Chow T, Korneluk RG (1999) A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection. Nat Cell Biol 1:190-192 (Pubitemid 129656025)
18. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B (2007) Mitochondria, oxidative stress and cell death. Apoptosis 12:913-922 (Pubitemid 46653300)
19. Agostinelli E, Seiler N (2006) Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids 31:341-355 (Pubitemid 44537062)
20. Choi SL, Kim SJ, Lee KT, Kim J, Mu J, Birnbaum MJ, Soo Kim S, Ha J (2001) The regulation of AMP-activated protein kinase by H(2)O(2). Biochem Biophys Res Commun 287:92-97 (Pubitemid 32912467)
21. Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV, Ardehali H (2009) Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 284:2080-2087
22. Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, Lyerly HK, Devi GR (2008) Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther 7:38-47
23. Amantana A, London CA, Iversen PL, Devi GR (2004) X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3:699-707 (Pubitemid 39193751)
24. Eruslanov E, Kusmartsev S (2010) Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 594:57-72
25. Elorza A, Hyde B, Mikkola HK, Collins S, Shirihai OS (2008) UCP2 modulates cell proliferation through the MAPK/ERK pathway during erythropoiesis and has no effect on heme biosynthesis. J Biol Chem 283:30461-30470
26. Miao L, St Clair DK (2009) Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med 47:344-356
27. Balendiran GK, Dabur R, Fraser D (2004) The role of glutathione in cancer. Cell Biochem Funct 22:343-352 (Pubitemid 39518098)
28. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W (2000) Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390-395
29. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8:579-591
30. Batinic-Haberle I (2002) Manganese porphyrins and related compounds as mimics of superoxide dismutase. Methods Enzymol 349:223-233
31. Fernandes AS, Gaspar J, Cabral MF, Rueff J, Castro M, Batinic-Haberle I, Costa J, Oliveira NG (2010) Protective role of orthosubstituted Mn(III) N-alkylpyridylporphyrins against the oxidative injury induced by tert-butylhydroperoxide. Free Radic Res 44:430-440
32. Saba H, Batinic-Haberle I, Munusamy S, Mitchell T, Lichti C, Megyesi J, MacMillan-Crow LA (2007) Manganese porphyrin reduces renal injury and mitochondrial damage during ischemia/reperfusion. Free Radic Biol Med 42:1571-1578 (Pubitemid 46591998)
33. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132
34. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97:1754-1759 (Pubitemid 30118515)
35. Jones RG, Thompson CB (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23:537-548
36. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527 (Pubitemid 44854747)
37. Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N et al (2008) Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res 68:759-766 (Pubitemid 351206752)
38. Hardie DG (2007) AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 47:185-210
39. Batinic-Haberle I, Reboucas JS, Spasojevic I (2010) Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal 13:877-918
40. Zhao Y, Chaiswing L, Oberley TD, Batinic-Haberle I, St Clair W, Epstein CJ, St Clair D (2005) A mechanism-based antioxidant approach for the reduction of skin carcinogenesis. Cancer Res 65:1401-1405 (Pubitemid 40270168)
41. Batinic-Haberle I, Spasojevic I, Tse HM, Tovmasyan A, Rajic Z, St Clair DK, Vujaskovic Z, Dewhirst MW, Piganelli JD (2010) Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids. doi:10.1007/s00726-010-0603-6
42. Kong Q, Beel JA, Lillehei KO (2000) A threshold concept for cancer therapy. Med Hypotheses 55:29-35 (Pubitemid 30612080)
43. Roninson IB, Brown JM, Bredesen DE (2008) Beyond apoptosis: cellular outcomes of cancer therapy. Informa Healthcare, New York
44. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22:517-528 (Pubitemid 41079781)
45. Halliwell B, Gutteridge JMC (1985) Free radicals in biology and medicine. Clarendon Press, Oxford University Press, Oxford, New York
46. Li S, Yan T, Yang JQ, Oberley TD, Oberley LW (2000) The role of cellular glutathione peroxidase redox regulation in the suppression of tumor cell growth by manganese superoxide dismutase. Cancer Res 60:3927-3939 (Pubitemid 32204589)
47. Landriscina M, Maddalena F, Laudiero G, Esposito F (2009) Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal 11:2701-2716
48. Khan G, Merajver S (2009) Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. Expert Opin Investig Drugs 18:541-548
49. Heikkila RE, Cabbat FS, Cohen G (1976) In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate. J Biol Chem 251:2182-2185